Lipoprotein(a) [0.03%]
脂蛋白(a)
K P Mellwig,A Vogt
K P Mellwig
Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results [0.03%]
脂蛋白(a)血液透析在周围动脉疾病患者中的应用：理论依据与临床结果
Norbert Weiss,Ulrich Julius
Norbert Weiss
Patients with symptomatic peripheral arterial disease (PAD) are at a very high risk of cardiovascular morbidity and mortality. Elevated lipoprotein(a) levels have been shown to be a risk factor for coronary artery disease (CAD) and stroke. ...
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region [0.03%]
LPA基因区Lp(a)浓度或遗传变异对心血管风险的预测价值
Florian Kronenberg
Florian Kronenberg
In the middle of the 1990s the interest in Lp(a) vanished after a few badly performed studies almost erased Lp(a) from the map of biological targets. However, since roughly 10 years the interest has begun to grow again mainly for two reason...
Anja Vogt
Anja Vogt
Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD) and Lp(a) is acknowledged as a risk factor to be included in risk assessment. The established lipid-modifying medical therapie...
U Julius,S Tselmin,U Schatz et al.
U Julius et al.
Lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor which is inherited and not changed by nutrition or physical activity. At present, only proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may mode...
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [0.03%]
脂蛋白(a)与转化生长因子亚型九抑制剂
U Julius,S Tselmin,U Schatz et al.
U Julius et al.
Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably othe...
Reinhard Klingel,Andreas Heibges,Cordula Fassbender
Reinhard Klingel
Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor playing a causal role for atherosclerotic cardiovascular disease (ASCVD). Early or progressive ASCVD or a familial predisposition are key findings which can be associated w...
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? [0.03%]
脂蛋白(a)是缺血性卒中和静脉血栓栓塞的危险因素吗？
Alexander Heinrich Nave,Arnold von Eckardstein
Alexander Heinrich Nave
The structural similarity with plasminogen as well as thrombogenic and atherogenic in vitro functions raise the question if lipoprotein(a) (Lp(a)) is a risk factor for venous thromboembolism (VTE) and ischemic stroke. Numerous case-control ...
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels [0.03%]
血脂吸附治疗可有效降低升高的Lp(a)水平
V J J Schettler,C L Neumann,C Peter et al.
V J J Schettler et al.
Lipoprotein(a) (Lp(a)) is a genetic risk factor for cardiovascular disease (CVD) and is associated with the induction and sustaining of atherosclerotic cardiovascular diseases (ASCVD). Since 2008 Lp(a) along with progressive CVD has been ap...
Erratum to: The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on [0.03%]
德国脂蛋白pheresis注册系统(GLAR):近五年来的情况(勘误版)
V J J Schettler,C L Neumann,C Peter et al.
V J J Schettler et al.
Published Erratum
Clinical research in cardiology supplements. 2017 Jul 17. DOI:10.1007/s11789-017-0092-1 2017